B. Scott

发表

Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft‐versus‐host disease: analysis of BMT CTN‐0201 and ‐0901 samples

D. Weisdorf, B. Blazar, A. Rashidi, 2018, British journal of haematology.

Survival following allogeneic transplant in patients with myelofibrosis.

N. Kröger, M. Arcasoy, S. Verstovsek, 2020, Blood advances.

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

M. Arcasoy, R. Ribeiro, S. Verstovsek, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Hemopoietic Cell Transplantation

H. Deeg, B. Scott, 2006 .

Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.

H. Deeg, J. Radich, S. Heimfeld, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hemopoietic cell transplantation for the myelodysplastic syndromes.

H. Deeg, B. Scott, 2003, Archivum immunologiae et therapiae experimentalis.

Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.

S. Pergam, R. Lynch, M. Shadman, 2020, JCO oncology practice.

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes

C. Craddock, B. Skikne, R. Champlin, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation

T. Braun, P. Hari, P. Westervelt, 2017, Bone Marrow Transplantation.

Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.

E. Estey, F. Appelbaum, T. Gooley, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy

H. Deeg, B. Sandmaier, D. Maloney, 2011, Bone Marrow Transplantation.

Last Marrow Standing: Bone Marrow Transplantation for Acquired Bone Marrow Failure Conditions

A. Gerds, B. Scott, 2012, Current Hematologic Malignancy Reports.

Delayed globin synthesis leads to excess heme and the macrocytic anemia of Diamond Blackfan anemia and del(5q) myelodysplastic syndrome

J. Abkowitz, B. Wood, A. Shimamura, 2016, Science Translational Medicine.

Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies

E. Estey, M. Othus, R. Walter, 2022, Leukemia.

Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.

S. Verstovsek, R. Mesa, J. Mascarenhas, 2020, Blood advances.

NCCN Myeloproliferative Neoplasms , Version 2 . 2017 Clinical Practice Guidelines in Oncology

K. Gregory, Hema M Sundar, S. Verstovsek, 2016 .

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.

H. Deeg, J. Radich, M. Sorror, 2012, Blood.

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients.

M. Aljurf, J. Szer, R. Gale, 2021, Transplantation and cellular therapy.

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients.

R. Vij, W. Wood, M. Aljurf, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia

H. Deeg, M. Sorror, B. Storer, 2019, Haematologica.

CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia.

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2018, Leukemia research.

Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia.

H. Deeg, Emily A. Stevens, B. Wood, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome.

B. Wood, B. Sandmaier, T. Gooley, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines

C. Bloomfield, R. Bejar, P. Greenberg, 2015 .

Clinical presentation and differential diagnosis

B. Scott, 2019, Fast Facts: Cutaneous T-cell Lymphoma.

Myelodysplastic Syndromes (MDS)

B. Scott, 2012 .

Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS).

H. Deeg, N. Kröger, M. Sorror, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Management of myelodysplastic syndromes: 2008 update.

E. Estey, B. Scott, 2008, Oncology.

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020, Leukemia & lymphoma.

A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

E. Estey, M. Othus, R. Walter, 2016 .

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study

E. Estey, D. Stirewalt, E. Pogosova-Agadjanyan, 2017, Leukemia.

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study

E. Estey, D. Stirewalt, M. Othus, 2014 .

A phase I/II study of oral clofarabine plus low‐dose cytarabine in previously treated acute myeloid leukaemia and high‐risk myelodysplastic syndrome patients at least 60 years of age

E. Estey, B. Wood, J. Pagel, 2015, British journal of haematology.

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome

H. Deeg, D. Porter, G. Gui, 2020, medRxiv.

The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis

S. Vesely, M. Crowther, C. Chai-Adisaksopha, 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD

D. Weisdorf, B. Blazar, A. Rashidi, 2018, Bone Marrow Transplantation.

Existing agents, novel agents, or transplantation for high-risk MDS.

B. Scott, 2020, Hematology. American Society of Hematology. Education Program.

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2015, Leukemia.

Optimization of allogeneic transplant conditioning: not the time for dogma

H. Deeg, M. Maris, E. Warren, 2006, Leukemia.

NF- κ B and FLIP in Arsenic Trioxide (ATO)-Induced Apoptosis in Myelodysplastic Syndromes (MDS)

H. Deeg, S. Seal, N. Abbasi, 2005 .

Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome

Connie Y. C. Ma, Amit Verma, P. Greenberg, 2021, Blood advances.

Myelodysplastic syndromes: increasing disease awareness. Discussion.

B. Scott, 2012, The American journal of medicine.

Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome

A. Karsan, U. Platzbecker, Sandy S Sung, 2013, Haematologica.

Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.

E. Leifer, N. Geller, D. Porter, 2021, Transplantation and cellular therapy.

The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis

R. Vij, Lixin Yang, M. Aljurf, 2022, Haematologica.

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.

Kaori Ito, A. Mead, Jennifer A. Smith, 2020, Blood advances.

Allogeneic transplantation for myelofibrosis with adverse risk karyotype: Attack on the clones?

B. Scott, J. Cooper, 2018, American journal of hematology.

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

E. Ranheim, K. Gregory, C. Fletcher, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis.

H. Deeg, C. McFarland, B. Storer, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis

M. Heuser, F. Thol, M. Robin, 2022, HemaSphere.

Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.

R. Storb, R. Farah, T. Gooley, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms

R. Storb, F. Baron, B. Sandmaier, 2019, Haematologica.

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

R. Larson, A. Yang, E. Wang, 2012, Journal of Hematology & Oncology.

Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States

D. Steensma, Xiaomei Ma, M. Sugrue, 2018, BMJ Open.

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

E. Estey, F. Appelbaum, R. Sandhu, 2012 .

Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells.

H. Deeg, F. Appelbaum, E. Petersdorf, 2004, Leukemia research.

Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes.

R. Storb, B. Storer, F. Appelbaum, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.

H. Deeg, K. Loeb, M. Sorror, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome.

R. Storb, B. Storer, F. Appelbaum, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

E. Leifer, N. Geller, H. Deeg, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

B. Skikne, G. Garcia-Manero, S. Gore, 2016 .

Undertreatment of Patients (Pts) with Myelodysplastic Syndromes (MDS): Analysis of a Large Electronic Medical Records (EMR) Database Cohort of US Pts with MDS

D. Steensma, Xiaomei Ma, M. Sugrue, 2016 .

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.

M. Maris, R. Storb, B. Sandmaier, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome.

E. Estey, F. Appelbaum, R. Walter, 2020, Blood advances.

Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm

E. Estey, M. Othus, R. Walter, 2019, Leukemia.

Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high‐risk MDS

E. Estey, B. Wood, J. Singer, 2016, British journal of haematology.

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

D. Niederwieser, R. Hoffman, A. Vannucchi, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies

B. Skikne, M. Savona, B. Scott, 2014, Journal of clinical pharmacology.

Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation

H. Deeg, B. Sandmaier, E. Warren, 2007, Bone Marrow Transplantation.

The Role of Donor Lymphocyte Infusion (DLI) in Post Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era.

R. Vij, M. Aljurf, J. Szer, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase.

H. Deeg, U. Popat, J. Capo-Chichi, 2020, Blood advances.

Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.

Y. Liu, M. Aljurf, J. Szer, 2020, Blood advances.

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

L. Pagano, M. Perales, I. Yakoub-Agha, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy of Myelodysplastic Syndrome (MDS) with Azacitidine Given in Combination with Etanercept: A Phase II Study.

B. Storer, S. Petersdorf, A. Ramakrishnan, 2007 .

Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.

E. Estey, M. Bar, B. Wood, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

S. Verstovsek, R. Mesa, M. Talpaz, 2021, Haematologica.

Randomized phase 1 study of sequential (“primed”) vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm

E. Estey, M. Othus, R. Walter, 2020, Leukemia & lymphoma.

PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis

Connie Y. C. Ma, P. Greenberg, A. Verma, 2018, Blood.

Treosulfan, Fludarabine and 2 Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with MDS and AML

E. Estey, M. Bar, B. Wood, 2014 .

Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis

Emily A. Stevens, T. Gooley, H. Deeg, 2019, Bone Marrow Transplantation.

When and how to transplant patients with myelofibrosis

H. Deeg, B. Scott, O. Sala-Torra, 2015 .

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines.

M. Robin, G. Garcia-Manero, Z. DeFilipp, 2022, Transplantation and cellular therapy.

Red blood cell transfusion-dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndromes (MDS)

H. Deeg, M. Sorror, P. Valent, 2009 .

Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

R. Collins, P. Greenberg, G. Gaidano, 2014 .

Pre-transplant Neutropenia Is Associated with Poor Risk Cytogenetic Features and Increased Infection-related Mortality in Patients with Myelodysplastic Syndromes

H. Deeg, R. Storb, F. Appelbaum, 2008 .

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for MDS and AML evolving from MDS

H. Deeg, B. Sandmaier, T. Gooley, 2016 .

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT® Myelodysplastic Syndromes (MDS) and AML Disease Registry

R. Bejar, D. Revicki, G. Garcia-Manero, 2016 .

Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms

E. Estey, M. Othus, R. Walter, 2018, Haematologica.

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

H. Deeg, M. Sorror, R. Storb, 2006, Leukemia.

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

H. Deeg, D. Porter, G. Gui, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades

P. Hari, M. Sorror, M. Maris, 2020, Haematologica.

It's Not All in the Conditioning or the Perils of Early Trial Cessation.

B. Scott, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation

B. Sandmaier, B. Scott, 2016 .

Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine.

P. Fenaux, L. Adès, U. Germing, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

H. Deeg, M. Sorror, M. Maris, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes with myeloid malignancies.

B. Sandmaier, B. Scott, 2006, Hematology. American Society of Hematology. Education Program.

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

D. Niederwieser, R. Hoffman, A. Reiter, 2018, Blood.

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.

H. Deeg, B. Wood, M. Sorror, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Genetics, prognosis, and transplantation for myelofibrosis

H. Deeg, Janghee Woo, R. Salit, 2018, Advances in Cell and Gene Therapy.

Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing.

T. Gooley, A. Gerds, H. Deeg, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders.

H. Deeg, B. Scott, 2006, Best practice & research. Clinical haematology.

Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis

I. Yakoub-Agha, D. Mclornan, A. Radujkovic, 2022, British journal of haematology.

Myelodysplastic syndromes, version 2.2015.

C. Bloomfield, H. Deeg, R. Bejar, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia.

B. Storer, F. Appelbaum, R. Hackman, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.

F. M. Stewart, M. Sorror, R. Storb, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission.

E. Estey, M. Sorror, B. Sandmaier, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome.

W. Leisenring, M. Loken, D. Wells, 2008, Blood.

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome

E. Leifer, P. Westervelt, F. Appelbaum, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

E. Leifer, P. Westervelt, F. Appelbaum, 2020, Transplantation and Cellular Therapy.

Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms

E. Estey, M. Othus, R. Walter, 2020, Leukemia & lymphoma.

Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes

H. Deeg, B. Storer, Janghee Woo, 2017, Haematologica.

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm

E. Estey, M. Othus, R. Walter, 2017, Haematologica.

Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste.

B. Scott, 2020, Blood advances.

Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.

H. Deeg, D. Maloney, E. Warren, 2019, Clinical lymphoma, myeloma & leukemia.

Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept

E. Estey, H. Deeg, B. Storer, 2010, British journal of haematology.

A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

E. Estey, J. Abkowitz, M. Othus, 2021, Blood.

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

M. Levis, M. Patnaik, A. Deol, 2020, Bone Marrow Transplantation.

Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms

E. Estey, F. Appelbaum, M. Othus, 2018, Leukemia.

Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study

E. Estey, R. Walter, P. Hendrie, 2014, Haematologica.

Preliminary Data from a Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning Is Well-Tolerated, Facilitates Chimerism and Clearance of Minimal Residual Disease in Older Adults with MDS/AML Undergoing Allogeneic HCT

L. Muffly, W. Pang, A. Artz, 2022, Transplantation and Cellular Therapy.

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

G. Garcia-Manero, J. Pons, J. Altman, 2021, Blood.

Germline predisposition variants occur in myelodysplastic syndrome patients of all ages.

S. Spellman, R. Sobecks, L. Godley, 2022, Blood.

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis

M. Heuser, F. Thol, N. Kröger, 2022, Blood Advances.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in T-cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.

J Wagner, F. Awan, M. Krem, 2022, Transplantation and cellular therapy.

disease following prior therapy or antecedent hematologic disorders syndrome: similar outcomes in patients with de novo disease and syndrome or acute myeloid leukemia arising from myelodysplastic Hematopoietic cell transplantation in patients with myelodysplastic

B. Clurman, B. Sandmaier, B. Storer, 2013 .

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders.

B. Clurman, H. Deeg, R. Storb, 2007, Blood.

Myeloablative Versus Nonmyeloablative Hemopoietic Cell Transplantation (HCT) for Patients with Myelodysplasia (MDS) or AML with Multilineage Dysplasia Following MDS (tAML).

M. Sorror, M. Maris, R. Storb, 2004 .

Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia.

H. Deeg, M. Sorror, R. Storb, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Targeted Busulfan and Cyclophosphamide as Compared to Busulfan and TBI as Preparative Regimens for Transplantation in Patients with Advanced MDS or Transformation to AML

H. Deeg, B. Storer, F. Appelbaum, 2004, Leukemia & lymphoma.

From the Guest Editor's Desk

H. Deeg, B. Scott, 2004 .

NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs).

H. Deeg, S. Seal, N. Abbasi, 2005, Blood.

Arsenic Trioxide (ATO) Induced Apoptosis in Myelodysplastic Syndrome (MDS): The Role of TNFa and NFkB.

H. Deeg, S. Seal, N. Abbasi, 2004 .

Anti‐thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study

B. Storer, S. Petersdorf, A. Ramakrishnan, 2010, British journal of haematology.

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.

H. Deeg, J. Radich, M. Sorror, 2012, Blood.

Impact of Genetic Mutations on the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia with Antecedent Myeloproliferative Neoplasm

U. Popat, J. Capo-Chichi, K. Ahn, 2020 .

Myelodysplastic syndromes.

H. Deeg, B. Scott, 2010, Annual Review of Medicine.

Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.

H. Deeg, Emily A. Stevens, M. Sorror, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

M. Cazzola, H. Deeg, N. Kröger, 2015, Blood.

Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Guillermo Garcia-Manero, Christopher R Cogle, G. Garcia-Manero, 2015, The oncologist.

Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial.

H. Deeg, B. Storer, Janghee Woo, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transplantation for myelodysplastic syndromes 2013

H. Deeg, B. Scott, J. Vaughn, 2013, Current opinion in hematology.

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.

R. Collins, P. Greenberg, G. Gaidano, 2016, The Lancet. Oncology.

Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.

R. Vij, M. Aljurf, R. Gale, 2022, JAMA oncology.

A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation.

M. Heuser, N. Kröger, M. Robin, 2021, Blood advances.

Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines

E. Ranheim, K. Gregory, C. Fletcher, 2017 .

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study

R. Bejar, G. Garcia-Manero, J. Maciejewski, 2016, BMC Cancer.

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study

R. Bejar, G. Garcia-Manero, J. Maciejewski, 2016, BMC Cancer.

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

H. Deeg, J. Wood, Z. Estrov, 2009 .

Tyrosine Kinase Inhibitors with or without Donor Lymphocyte Infusion Continue to Provide Long-Term Survival after Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation

U. Popat, R. Sobecks, W. Saber, 2018, Blood.

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.

B. Sandmaier, T. Gooley, H. Deeg, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced Incidence of Acute and Chronic Graft-versus-Host Disease (GvHD) without Increased Relapse in Patients with High-Risk Myeloid Disorders Given Thymoglobulin (THY) as Part of the Transplant Conditioning Regimen: A Dose-Finding Study.

R. Storb, B. Storer, G. McDonald, 2004 .

Treatment of Recurrent or Persistent AML/MDS After Allogeneic Hematopoietic Cell Transplantation with Azacitidine.

E. Estey, R. Storb, B. Sandmaier, 2010 .

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML

M. Patnaik, A. Deol, R. Maziarz, 2018, Blood.

Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

C. Craddock, B. Skikne, R. Champlin, 2017 .

Long-Term Follow up of BMT CTN 0901, a Randomized Phase III Trial Comparing Myeloablative (MAC) to Reduced Intensity Conditioning (RIC) Prior to Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) (MAvRIC Trial)

B. Scott, 2020 .

Radius: Midostaurin (mido) Plus Standard of Care (SOC) after Allogeneic Stem Cell Transplant (alloSCT) in Patients (pts) with FLT3-Internal Tandem Duplication (ITD)–Mutated Acute Myeloid Leukemia (AML)

M. Levis, M. Patnaik, A. Deol, 2019, Biology of Blood and Marrow Transplantation.

Relationship between Conditioning Intensity and Comorbidity in Patients (Pts) with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Receiving Allogeneic Hematopoietic Cell Transplantation (HCT).

M. Sorror, M. Maris, R. Storb, 2005 .

Diagnosis of pulmonary hypertension by noninvasive methods in hematopoietic cell transplant patients with myelofibrosis

G. Kicska, R. Edwards, T. Gooley, 2019, Bone Marrow Transplantation.

M. Walter, P. Westervelt, J. Dipersio, 2021, Blood.

Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry

R. Bejar, D. Revicki, G. Garcia-Manero, 2020, EJHaem.

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

S. Verstovsek, A. Vannucchi, M. McMullin, 2022, EJHaem.

BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.

S. Verstovsek, A. Vannucchi, S. Koschmieder, 2022, Future oncology.

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

S. Verstovsek, J. Mascarenhas, A. Gerds, 2022, Blood advances.

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

K. Gregory, Hema M Sundar, S. Verstovsek, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes

D. Revicki, G. Garcia-Manero, J. Maciejewski, 2020, International journal of laboratory hematology.

JAK/STAT Pathway Inhibitors and Neurologic Toxicity: Above All Else Do No Harm?

P. Becker, Bart L Scott, B. Scott, 2015, JAMA oncology.

Impact of Pretransplant Neutropenia on Post-Transplant Outcome in Patients with Myelodysplastic Syndrome (MDS).

B. Storer, M. Boeckh, K. Marr, 2006 .

Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care

D. Revicki, G. Garcia-Manero, J. Maciejewski, 2023, Transplantation and cellular therapy.

Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2012 .

Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis.

H. Deeg, Z. Estrov, H. Kantarjian, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML)

M. Patnaik, A. Deol, R. Maziarz, 2016 .

International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis

H. Deeg, B. Sandmaier, F. Appelbaum, 2010 .

Low Albumin, High Ferritin, and Thrombocytopenia Before Transplant Predict Non-Relapse Mortality (NRM) Independent of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI).

M. Sorror, R. Storb, B. Sandmaier, 2009 .

Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high‐risk myelodysplastic syndrome

E. Estey, J. Pagel, R. Walter, 2015, American journal of hematology.

Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design

E. Estey, F. Appelbaum, J. Pagel, 2014, British Journal of Haematology.

Reduced intensity hematopoietic stem cell transplantation for myelofibrosis in accelerated-phase

M. Heuser, F. Thol, N. Kröger, 2022, Blood Advances.

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis

A. Mead, R. Mesa, C. Harrison, 2021, Haematologica.

Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis

H. Deeg, Z. Estrov, H. Kantarjian, 2010 .

Transplant Referral Patterns for Patients (Pts) with Newly Diagnosed (ND) Higher-Risk (HR) Myelodysplastic Syndromes (MDS), and European Leukemianet (ELN) 2010 Intermediate-Risk (IR) or Adverse-Risk (AR) Acute Myeloid Leukemia (AML) in the Connect® MDS/AML Registry

D. Steensma, M. Sekeres, D. Pollyea, 2020 .

Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib.

R. Collins, P. Greenberg, G. Gaidano, 2015 .

Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.

R. Collins, P. Greenberg, G. Gaidano, 2015 .

G‐CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm

E. Estey, J. Abkowitz, F. Appelbaum, 2015, American journal of hematology.

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

I. Yakoub-Agha, M. Aljurf, R. Gale, 2023, Blood advances.

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML

E. Estey, J. Abkowitz, M. Othus, 2023, Blood Advances.

E. Estey, E. Pogosova-Agadjanyan, M. Othus, 2017, Leukemia.

Emerging importance of mutational analysis in myelodysplastic syndrome and acute myelogenous leukemia.

M. Walter, A. Gerds, B. Scott, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms

E. Estey, T. Gooley, R. Walter, 2023, Leukemia & lymphoma.

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation.

M. Heuser, F. Thol, M. Robin, 2023, Blood.

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

C. Craddock, B. Skikne, R. Champlin, 2014 .

Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis

M. Aljurf, R. Gale, K. Ballen, 2023, Haematologica.